Cortactin antibody in myasthenia gravis and its clinical significance
10.3760/cma.j.issn.1006-7876.2018.06.007
- VernacularTitle:重症肌无力患者血清抗皮动蛋白抗体的检测及其临床意义
- Author:
Meiqiu CHEN
1
;
Lan CHU
;
Yifan ZHANG
;
Shixiang KUANG
;
Dian HE
;
Cong XIA
;
Yuan LI
;
Qingfang ZHANG
;
Ting LUO
Author Information
1. 贵州医科大学附属医院神经内科
- Keywords:
Myasthenia gravis;
Cortactin;
Autoantibodies
- From:
Chinese Journal of Neurology
2018;51(6):438-443
- CountryChina
- Language:Chinese
-
Abstract:
Objective To investigate the clinical significance of cortactin antibody in myasthenia gravis (MG).Methods Cortactin antibody in the serum of 100 MG patients, 40 normal controls and 40 other neuroimmune diseases patients was examined by Western blotting and ELISA using purified recombinant human protein cortactin as antigen .Acetylcholine receptor antibody ( AchR-ab ) and muscle specific kinase antibody (MuSK-ab) were parallely measured by ELISA.Results Antibodies to cortactin were found in nine (9％) serum samples of 100 MG patients.Four of the nine cortactin antibody positive sera were also positive for AChR-ab.The rest five MG patients only had antibodies against cortactin ( no detectable AChR-ab or MuSK-ab).None of the control subjects (including 40 normal controls and 40 other neuroimmune diseases patients ) had cortactin antibodies.Most (7/9) of the cortactin antibody positive MG patients presented with early-onset subgroup.Patients only with cortactin antibodies did not appear to have thymoma.Patients with MG who had both AChR and cortactin antibodies showed maximum involvement of muscles and severe Osserman's classification ( three cases of type ⅡB and one case of type Ⅳ) . Conclusion Cortactin antibody may be a new antibody for MG , which can provide clues for further exploring the potential pathogenic mechanisms of the disease .
